Colon

ALLIANCE A212102 AT MBMC ONLY As of 2/22/23 participants without a cancer diagnosis will be Temporarily Closed to Enrollment White female participants under (<) age 60 without a cancer diagnosis will temporarily be suspended on 12/1/22 3:30 cst

Blinded Reference Set For Multicancer Early Detection Blood Tests

URCC 19075 MBMC ONLY (Temporarily Closed to Enrollment)

Multi-Center Randomized Controlled Phase II Trial of Exercise to Treat Chemotherapy-Induced Peripheral Neuropathy (CIPN)

A222004 (JIT – If a possible patient is identified, notify CRA asap as it will take time to open trial through NCORP)

A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia

URCC-21038

Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting

NCI 10323

Cancer Moonshot Biobank Research Protocol

NSABP C-14 / CORRECT-MRD II

Second Colorectal Cancer Clinical Validation Study to Predict Recurrence Using a Circulating Tumor DNA Assay to Detect Minimal Residual Disease

A221805 EFFECTIVE 3/31/23, at 7am CST, the Phase II portion of the study will permanently close to new patient accrual. Information regarding the status of the Phase III component will be sent upon completion of the Phase II analyses. If the analysis is positive, a reactivation notice will be distributed at the time A221805 opens to Phase III enrollment.

Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study

Clinical Trials

Quick Links